본문

서브메뉴

Development of Molecular Glue Degraders as Probes and Therapeutic Agents- [electronic resource]
내용보기
Development of Molecular Glue Degraders as Probes and Therapeutic Agents- [electronic resource]
자료유형  
 학위논문
Control Number  
0016932293
International Standard Book Number  
9798379612566
Dewey Decimal Classification Number  
574
Main Entry-Personal Name  
Miyamoto, David.
Publication, Distribution, etc. (Imprint  
[S.l.] : Harvard University., 2023
Publication, Distribution, etc. (Imprint  
Ann Arbor : ProQuest Dissertations & Theses, 2023
Physical Description  
1 online resource(497 p.)
General Note  
Source: Dissertations Abstracts International, Volume: 84-12, Section: B.
General Note  
Includes supplementary digital materials.
General Note  
Advisor: Woo, Christina.
Dissertation Note  
Thesis (Ph.D.)--Harvard University, 2023.
Restrictions on Access Note  
This item must not be sold to any third party vendors.
Summary, Etc.  
요약Immunomodulatory drugs (IMiDs) function as molecular glues between the E3 ligase substrate receptor cereblon (CRBN) and protein substrates. The formation of this ternary complex results in the substrates' ubiquitination and proteasomal degradation. The field of targeted protein degradation has extensively utilized this unique mechanism of action to degrade various protein substrates to study biological processes and for therapeutic applications. Here, using a structure-guided approach, I develop novel small molecules based on the IMiDs to degrade various proteins implicated in disease.In chapter 1, I discuss the history of the IMiDs and describe the structural basis for their substrate scope. I review the major proteins that are degraded by the IMiDs and how they were discovered and the structural basis for the IMiD's engagement of neosubstrates. I also discuss the ongoing efforts to degrade these substrates and their therapeutic applications in various diseases.In chapter 2, I report the medicinal chemistry efforts to develop a small molecule that degrades the transcription factor Ikaros zinc finger protein 2 (IKZF2) and casein kinase 1 alpha (CK1α) both of which are targets in acute myeloid leukemia (AML). I discuss the structural basis for changing the selectivity of the IMiD lenalidomide to degrade IKZF2 and describe the small library of molecules based on its scaffold that I synthesized. I then detail the extensive medicinal chemistry efforts to optimize IKZF2 degradation to afford lead compound 35. I show that 35 additionally degrades CK1α and describe efforts to optimize 35 for solubility and metabolic stability. These efforts resulted in degrader 77 which potently degrades IKZF2 and CK1α and shows cell killing activity in AML and ovarian cancer cell lines.In chapter 3 I report the use of 35 and 77 in the context of AML. I report that 35 and 77 degrade IKZF2 and CK1α across multiple AML cell lines and induce apoptosis and differentiation. I then describe the validation of these molecules as molecular glues and show using a high throughput screen that they are selective against certain cancer types including AML. I then report the phenotypic effects of IKZF2 and CK1α degradation separately and find that IKZF2 degradation leads to differentiation while CK1α degradation leads to apoptosis, cell cycle arrest, and differentiation. Finally, I report the use of 35 and 77 in vivo in various AML models and show that 77 treatment delays AML disease progression and nearly double the lifespan of mice with AML.Finally, in chapter 4 I describe efforts to develop chemical tools to study small molecule-protein interactions. While not directly related to protein degradation with molecular glues, this chapter highlights the ability of chemical tools to reveal structural insights into small molecule-protein interactions such as those discussed in previous chapters. I describe the development and optimization of a cleavable biotin picolyl azide probe that can be used to identify small molecule binding sites. Using this probe, I report a novel binding site of celecoxib on prostaglandin E synthase.
Subject Added Entry-Topical Term  
Cellular biology.
Subject Added Entry-Topical Term  
Pharmaceutical sciences.
Subject Added Entry-Topical Term  
Immunology.
Index Term-Uncontrolled  
Immunomodulatory drugs
Index Term-Uncontrolled  
Proteasomal degradation
Index Term-Uncontrolled  
Metabolic stability
Index Term-Uncontrolled  
Molecular glue degraders
Index Term-Uncontrolled  
Therapeutic agents
Index Term-Uncontrolled  
Chemical tools
Added Entry-Corporate Name  
Harvard University Chemistry and Chemical Biology
Host Item Entry  
Dissertations Abstracts International. 84-12B.
Host Item Entry  
Dissertation Abstract International
Electronic Location and Access  
로그인을 한후 보실 수 있는 자료입니다.
Control Number  
joongbu:641815
신착도서 더보기
최근 3년간 통계입니다.

소장정보

  • 예약
  • 캠퍼스간 도서대출
  • 서가에 없는 책 신고
  • 나의폴더
소장자료
등록번호 청구기호 소장처 대출가능여부 대출정보
TQ0027729 T   원문자료 열람가능/출력가능 열람가능/출력가능
마이폴더 부재도서신고

* 대출중인 자료에 한하여 예약이 가능합니다. 예약을 원하시면 예약버튼을 클릭하십시오.

해당 도서를 다른 이용자가 함께 대출한 도서

관련도서

관련 인기도서

도서위치